Skip to main content
SpringerLink
Log in

Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The relationship between the debrisoquine oxidation status and the metabolism of clomipramine was studied in nine healthy volunteers (five rapid hydroxylators, three slow hydroxylators and one of intermediate status). The hydroxylation of clomipramine and demethylclomipramine were found to covary with that of debrisoquine, whereas demethylation of clomipramine seemed to be independent of the debrisoquine hydroxylation phenotype. The steady-state blood concentrations of clomipramine and its three main metabolites were measured in 122 depressed patients. Thirteen patients who concomitantly received a neuroleptic tended to have higher levels of demethylclomipramine and clomipramine, whereas the levels of the hydroxylated metabolites were hardly affected. Benzodiazepine co-administration did not modify the pharmacokinetics of clomipramine. The results suggest that benzodiazepines rather than levomepromazine should be used in depressed patients with anxiety and/or agitation in combination with the antidepressant treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Luskombe DK (1979) Pharmacokinetics of clomipramine. Br J Clin Pract (Suppl 3) 35–50

    Google Scholar 

  2. Sjöqvist F, Bertilsson L (1984) Clinical pharmacology of antidepressant drugs: Pharmacogenetics. In: Usdin E, Åsberg M, Bertilsson L, Sjöqvist F (eds) Frontiers in biochemical and pharmacological research in depression. Raven Press, New York, pp 359–372

    Google Scholar 

  3. Potter WZ, Calil HM, Sufin TA, Zavadil AP, Jusko WZ, Rapopert J, Goodwin FK (1982) Active metabolites of imipramine and desipramine in man. Clin Pharmacol Ther 31: 394–401

    Google Scholar 

  4. Mellström B, Bertilsson L, Säwe J, Schulz HV, Sjöqvist F (1981) E and Z-10 hydroxylation of nortriptyline: Relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 30: 189–193

    Google Scholar 

  5. Bertilsson L, Åsbeg-Wistedt A (1983) The debrisoquine hydroxylation test predicts steady-state plasma of desipramine. Br J Clin Pharmacol 15: 388–390

    Google Scholar 

  6. Balant-Gorgia AE, Schulz P, Dayer P, Balant LP, Gertsch C, Garrone G (1982) Role of oxidation polymorphism on blood and urine concentrations of amitriptyline and its metabolites in man. Arch Psychiatr Nervenkr 232: 215–222

    Google Scholar 

  7. Dayer P, Balant LP, Courvoisier F, Küpfer A, Kubli A, Balant-Gorgia A, Fabre J (1982) The genetic control of bufuralol in man. Eur J Drug Metab Pharmacokinet 7: 33–77

    Google Scholar 

  8. Alvan G, Griud M, Graffner C, Sjöqvist F (1984) Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism. Clin Pharmacol Ther 36: 515–519

    Google Scholar 

  9. Spina E, Birgersson C, von Bahr C, Ericsson Ö, Mellström B, Sheiner E, Sjöqvist F (1984) Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes. Clin Pharmacol Ther 36: 677–682

    Google Scholar 

  10. Mellström B, Bertilsson L, Träskman L, Rollins D, Åsberg M, Sjöqvist F (1979) Intraindividual similarity in the metabolism of amitriptyline and chlorimipramine in depressed patients. Pharmacology 19: 282–287

    Google Scholar 

  11. Alexanderson B (1973) Prediction of steady-state plasma levels of nortriptyline from single oral dose kinetics. A study in twins. Eur J Clin Pharmacol 6: 44–53

    Google Scholar 

  12. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2: 584–586

    Google Scholar 

  13. Idle JR, Smith RL (1984) The debrisoquine hydroxylation gene: a gene of multiple consequence. In: Lemberger L, Reidenberg M (eds) Proceedings of the Second World Conference on Clin Pharm Ther ASPET, Bethesda pp 148–164

  14. Von Bahr C, Spina E, Birgersson C, Ericson Ö, Göranson M, Henthorn T, Sjöqvist F (1985) Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochem Pharmacol 34: 2501–2505

    Google Scholar 

  15. Suckow RF, Cooper TB (1981) Simultaneous determination of imipramine, desipramine and their 2-hydroxymetabolites in plasma by ion-pain reversed-phase high-performance liquid chromatography with amperometric detection. J Pharm Sci 70 (3): 257–261

    Google Scholar 

  16. Jones RB, Luskombe DK (1977) Plasma concentrations of clomipramine and its N-desmethylmetabolite in depressive patients following treatment with various dosage regimes of clomipramine. Postgrad Med J 53 [Suppl 4]: 63–76

    Google Scholar 

  17. Hammer W, Sjöqvist F (1967) Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sci 6: 1895–1903

    Google Scholar 

  18. Mellström B, von Bahr C (1981) Demethylation and hydroxylation of amitriptyline, nortriptyline and 10-hydroxyamitriptyline in human liver microsomes. Drug Metab Dispos 9: 565–568

    Google Scholar 

  19. Potter WZ, Matthew VR, Lane EA (1984) Active metabolites of antidepressants: Pharmacodynamics and relevant pharmacokinetics. In: Usdin E, Åsberg M, Bertilsson L, Sjöqvist F (eds) Frontiers in biochemical and pharmacological research in depression. Raven Press, New York, pp 373–390

    Google Scholar 

  20. Gram LF, Overo KF (1972) Drug interaction inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man. Br Med J 1: 463–465

    Google Scholar 

  21. Boissier JR, Tillement JP, Martin D, Pichot P (1975) Effets de la lévomépromazine sur le métabolisme de l'imipramine chez l'homme. J Pharmacol Clin 1 (Suppl 2): 11–15

    Google Scholar 

  22. Gram LF (1975) Effects of perphenazine on imipramine metabolism in man. Psychopharmacol Commun 1: 165–175

    Google Scholar 

  23. Siris SG, Cooper TB, Rifkin AE et al (1982) Plasma imipramine concentrations in patients receiving concomitant fluphenazine decanoate. Am J Psychiatry 139: 104

    Google Scholar 

  24. Bock JL, Nelson CJ, Gray S, Jatlow PL (1983) Desipramine hydroxylation. Variability and effect of antipsychotic drugs. Clin Pharmacol Ther 3: 322–328

    Google Scholar 

  25. Nelson JC, Jatlow PL (1980) Neuroleptic effect on desipramine steady-state plasma concentrations. Am J Psychiatry 137: 1232–1234

    Google Scholar 

  26. Hirschowitz J, Bennett JA, Zemlan FP, Gaiver DL (1983) Thioridazine effect on desipramine plasma levels. J Clin Psychopharmacol 3: 376–379

    Google Scholar 

  27. Gram LF, Overo KF, Kirk L (1974) Influence of neuroleptics and benzodiazepines on metabolism of tricyclic antidepressants in man. Am J Psychiatry 131: 836–866

    Google Scholar 

  28. Loga S, Curry S, Lader M (1981) Interaction of chlorpromazine and nortriptyline in patients with schizophrenia. Clin Pharmacokinet 6: 454–462

    Google Scholar 

  29. Otton SV, Inaba T, Kalow W (1984) Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs. Life Sci 34: 73–80

    Google Scholar 

  30. Lehmann T, Dayer P, Meyer UA (1986) Single dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers. Eur J Clin Pharmacol 29: 739–744

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Therapeutic Monitoring Unit, Department of Psychiatry, University of Geneva, Geneva, Switzerland

    A. E. Balant-Gorgia, L. P. Balant, Ch. Genet, J. M. Aeschlimann & G. Garrone

  2. Clinical Pharmacology Unit, Department of Medicine, University of Geneva, Geneva, Switzerland

    P. Dayer & J. M. Aeschlimann

Authors
  1. A. E. Balant-Gorgia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. P. Balant
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ch. Genet
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Dayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. M. Aeschlimann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Garrone
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Balant-Gorgia, A.E., Balant, L.P., Genet, C. et al. Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites. Eur J Clin Pharmacol 31, 449–455 (1986). https://doi.org/10.1007/BF00613523

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00613523

Key words

Search

Navigation